Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ARTC vs CNMD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CNMD Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–3 Matrix Metrics)

CNMD Overall Winner 6-Pillar Tally: ARTC 0 – 6 CNMD Matrix Metrics: ARTC 3 – 7 CNMD

As of Nov 20, 2026, CONMED Corporation (CNMD) is the stronger overall head-to-head candidate over ARTC (ARTC) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ARTC carries a Unified Composite Score of 62.3/100 (BUY) at $10.05 (N/M Forward P/E, N/A operating margin), whereas CNMD carries 49.1/100 (HOLD) at $46.56 (9.8x Forward P/E, 10.2% operating margin).

  • Composite vs. Pillar Nuance: While ARTC currently prints a higher short-term Unified Composite Score (62.3/100 BUY vs. CNMD 49.1/100 HOLD), CNMD captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (10.2% vs. N/A operating margin) and revenue trajectory (-0.7% vs. N/A YoY).
  • Technical & Structure Timing Caution: ARTC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 58.2); meanwhile CNMD is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 42.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ARTC vs CNMD
ARTC US Equity
ARTC
Institutional Equity
$10.05
+0.2% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.02β · 2% Vol
Unified Composite Score
62.3 / 100 BUY
Tech 67.0 Fund 57.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 58
RSI-14: 58.2 · SMA20: $9.99 · SMA50: $9.97
CNMD NYSE Head-to-Head Winner
CONMED Corporation
Electromedical & Electrotherapeutic Apparatus
$46.56
+0.39% 1D
Market Cap $1.4B
TTM Revenue $1.37B
Forward P/E 9.8x
Beta / 30D Vol 0.82β · 58% Vol
Unified Composite Score
49.1 / 100 HOLD
Tech 34.0 Fund 50.0 Flow 65.0 Mom 54.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.5%) with fading momentum, RSI 43
RSI-14: 42.7 · SMA20: $48.81 · SMA50: $47.23

6-Pillar Scorecard Institutional Category Breakdown (ARTC 0 – 6 CNMD)

Columns: Metric · ARTC · CNMD
1. Valuation Multiples CNMD
Forward P/E N/M 9.8x
Trailing P/E N/M 19.2x
PEG Ratio N/M 1.84x
EV / Revenue N/M 1.6x
2. Growth & Scale CNMD
Revenue Growth (YoY) N/A -0.7%
Earnings Growth (YoY) N/A +633.3%
TTM Revenue (USD) N/A $1.37B
Market Cap N/A $1.4B
3. Profitability & Quality CNMD
Gross Margin N/A 54.8%
Operating Margin N/A 10.2%
Net Profit Margin N/A 5.4%
Return on Equity (ROE) N/A 7.1%
4. Balance Sheet & Cash Flow CNMD
Cash Generation (TTM) N/A $133M
Cash Flow Margin N/A 9.7%
Net Cash / Leverage N/A ROE $768M Net Debt (0.77x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CNMD
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 35.6% (2nd %ile)
Put/Call OI Skew N/A 0.07x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Distribution
6. R&D & Supply-Chain Moat CNMD
OpEx & R&D Intensity N/A 44.6% of Rev ($611M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ARTC (3) vs CNMD (7)
Institutional Metric ARTC CNMD Criterion Row Edge
Market Capitalization
Scale
N/A $1.4B Larger Scale CNMD
Trailing P/E Ratio
Valuation
N/M 19.2x Lower Multiple CNMD
Forward P/E Ratio
Valuation
N/M 9.8x Lower Multiple CNMD
Revenue Growth (YoY)
Growth
N/A -0.7% Higher Growth CNMD
Operating Margin (TTM)
Profitability
N/A 10.2% Higher Margin CNMD
Net Profit Margin
Profitability
N/A 5.4% Higher Margin CNMD
Return on Equity (ROE)
Capital Efficiency
N/A 7.1% Higher ROE CNMD
52-Week Range Position
Momentum
100% ($10–$10) 65% ($31–$55) Stronger Trend ARTC
Beta / 30D Volatility
Risk Regime
-0.02β · 2% Vol 0.82β · 58% Vol Lower Realized Risk ARTC
Unified Institutional Score
Composite Signal
62.3 / 100 (BUY) 49.1 / 100 (HOLD) Higher Composite ARTC
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.37B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 54.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.84x PEG · 1.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $133M ($768M Net Debt (0.77x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CNMD +0.68 pp
ARTC: +0.3% · CNMD: +0.98%
3M Horizon CNMD +31.5 pp
ARTC: +0.6% · CNMD: +32.1%
6M Horizon CNMD +21.43 pp
ARTC: +2.55% · CNMD: +23.98%
1Y Horizon ARTC +1.41 pp
ARTC: +2.24% · CNMD: +0.83%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ARTC vs CNMD. Trailing 12-month operating profitability (ARTC N/A vs CNMD 10.2%) and valuation multiples (ARTC N/M vs CNMD 9.8x Forward P/E) are benchmarked directly in Pillar 4 below.

ARTC ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
CNMD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.37B
Gross Margin54.8%
Op. Margin10.2%
ROE / Fwd P/E7.1% · 9.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ARTC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ARTC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CNMD CONSOLIDATION
78d in phase · OBV DISTRIBUTION
Current IV 35.6%
IV Percentile 2nd %ile
Put/Call OI Skew 0.07x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CNMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ARTC Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CNMD Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.4B market capitalization and 10.2% operating margin.
OpEx & R&D Reinvestment 44.6% of Rev ($611M)
90D Engineering Disclosures 0 Published

Investor FAQ ARTC vs CNMD Key Questions & Quantitative Answers

As of Nov 20, 2026, CONMED Corporation (CNMD) is the stronger overall head-to-head candidate over ARTC (ARTC) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ARTC carries a Unified Composite Score of 62.3/100 (BUY) at $10.05 (N/M Forward P/E, N/A operating margin), whereas CNMD carries 49.1/100 (HOLD) at $46.56 (9.8x Forward P/E, 10.2% operating margin). Composite vs. Pillar Nuance: While ARTC currently prints a higher short-term Unified Composite Score (62.3/100 BUY vs. CNMD 49.1/100 HOLD), CNMD captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (10.2% vs. N/A operating margin) and revenue trajectory (-0.7% vs. N/A YoY). Technical & Structure Timing Caution: ARTC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 58.2); meanwhile CNMD is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 42.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CNMD leads the Growth & Scale pillar: ARTC posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with CNMD at -0.7% YoY revenue growth and +633.3% YoY earnings growth on $1.37B TTM revenue (54.8% gross margin, 10.2% operating margin). On trailing 12-month operating scale, ARTC generates N/A in USD-normalized revenue versus $1.37B for CNMD. In operating R&D and SG&A reinvestment, ARTC deploys N/A (0 90-day corporate R&D disclosures) versus 44.6% of Rev ($611M) (0 disclosures) for CNMD.

CNMD screens cheaper on headline valuation multiples. ARTC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CNMD trades at 9.8x Forward P/E, 19.2x Trailing P/E, 1.84x PEG, and 1.6x EV/Revenue (9.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ARTC (N/A ROE) versus CNMD (7.1% ROE) capital efficiency.

In options market volatility and institutional positioning, ARTC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 2% Vol realized risk). By comparison, CNMD carries 35.6% implied volatility (2nd %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.82β · 58% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.